Phase I Study of Subconjunctival Ranibizumab in Patients With Primary Pterygium Undergoing Pterygium Surgery

Anat Galor, Sonia H Yoo, Fernanda V R Piccoli, Artur J. Schmitt, Victoria Chang, Victor L Perez Quinones

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Purpose: To evaluate the safety and tolerability of ranibizumab given via subconjunctival injection in patients with primary pterygium undergoing pterygium surgery with autograft placement. Design: Prospective, open-label pilot study. Methods: Setting: Single-center, academic practice. Study Population: Ten patients with primary pterygia. bservational Procedure: Subconjunctival ranibizumab (0.5 mg/0.05 mL) administered at the limbus, adjacent to pterygium either 3 days prior to surgery (Group 1, n = 5) or at the time of surgery (Group 2, n = 5). Patients prospectively followed for 6 months after injection. Main Outcome Measures: Safety and tolerability of subconjunctival ranibizumab as determined by patient reporting, clinical examination, and masked observer interpretation of slit-lamp photographs. Results: The median age at presentation was 59 years (range 33 to 71 years); 60% of patients were male. Five patients were randomly assigned to be injected with 0.05 mg ranibizumab via subconjunctival injection 3 days prior to surgery; an additional 5 patients were injected with ranibizumab at the time of surgery. All 10 patients tolerated the injection well. The conjunctival autograft remained intact in the 9 patients whose grafts were secured with sutures. There was dehiscence of the autograft in the 1 patient whose graft was secured with fibrin glue. No other safety concerns arose after 6 months of follow-up. Three pterygium recurrences were noted at 6 months (all patients in Group 1). All remaining patients had a normal surgical bed appearance. Conclusions: The data from this small pilot study suggest that 1 subconjunctival injection of ranibizumab in conjunction with pterygium surgery is well tolerated.

Original languageEnglish
JournalAmerican Journal of Ophthalmology
Volume149
Issue number6
DOIs
StatePublished - Jun 1 2010

Fingerprint

Pterygium
Autografts
Injections
Safety
Ranibizumab
Transplants
Fibrin Tissue Adhesive
Sutures

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Phase I Study of Subconjunctival Ranibizumab in Patients With Primary Pterygium Undergoing Pterygium Surgery. / Galor, Anat; Yoo, Sonia H; Piccoli, Fernanda V R; Schmitt, Artur J.; Chang, Victoria; Perez Quinones, Victor L.

In: American Journal of Ophthalmology, Vol. 149, No. 6, 01.06.2010.

Research output: Contribution to journalArticle

Galor, Anat ; Yoo, Sonia H ; Piccoli, Fernanda V R ; Schmitt, Artur J. ; Chang, Victoria ; Perez Quinones, Victor L. / Phase I Study of Subconjunctival Ranibizumab in Patients With Primary Pterygium Undergoing Pterygium Surgery. In: American Journal of Ophthalmology. 2010 ; Vol. 149, No. 6.
@article{fc975ac4ee0d49bf91399065b1634111,
title = "Phase I Study of Subconjunctival Ranibizumab in Patients With Primary Pterygium Undergoing Pterygium Surgery",
abstract = "Purpose: To evaluate the safety and tolerability of ranibizumab given via subconjunctival injection in patients with primary pterygium undergoing pterygium surgery with autograft placement. Design: Prospective, open-label pilot study. Methods: Setting: Single-center, academic practice. Study Population: Ten patients with primary pterygia. bservational Procedure: Subconjunctival ranibizumab (0.5 mg/0.05 mL) administered at the limbus, adjacent to pterygium either 3 days prior to surgery (Group 1, n = 5) or at the time of surgery (Group 2, n = 5). Patients prospectively followed for 6 months after injection. Main Outcome Measures: Safety and tolerability of subconjunctival ranibizumab as determined by patient reporting, clinical examination, and masked observer interpretation of slit-lamp photographs. Results: The median age at presentation was 59 years (range 33 to 71 years); 60{\%} of patients were male. Five patients were randomly assigned to be injected with 0.05 mg ranibizumab via subconjunctival injection 3 days prior to surgery; an additional 5 patients were injected with ranibizumab at the time of surgery. All 10 patients tolerated the injection well. The conjunctival autograft remained intact in the 9 patients whose grafts were secured with sutures. There was dehiscence of the autograft in the 1 patient whose graft was secured with fibrin glue. No other safety concerns arose after 6 months of follow-up. Three pterygium recurrences were noted at 6 months (all patients in Group 1). All remaining patients had a normal surgical bed appearance. Conclusions: The data from this small pilot study suggest that 1 subconjunctival injection of ranibizumab in conjunction with pterygium surgery is well tolerated.",
author = "Anat Galor and Yoo, {Sonia H} and Piccoli, {Fernanda V R} and Schmitt, {Artur J.} and Victoria Chang and {Perez Quinones}, {Victor L}",
year = "2010",
month = "6",
day = "1",
doi = "10.1016/j.ajo.2010.01.015",
language = "English",
volume = "149",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "6",

}

TY - JOUR

T1 - Phase I Study of Subconjunctival Ranibizumab in Patients With Primary Pterygium Undergoing Pterygium Surgery

AU - Galor, Anat

AU - Yoo, Sonia H

AU - Piccoli, Fernanda V R

AU - Schmitt, Artur J.

AU - Chang, Victoria

AU - Perez Quinones, Victor L

PY - 2010/6/1

Y1 - 2010/6/1

N2 - Purpose: To evaluate the safety and tolerability of ranibizumab given via subconjunctival injection in patients with primary pterygium undergoing pterygium surgery with autograft placement. Design: Prospective, open-label pilot study. Methods: Setting: Single-center, academic practice. Study Population: Ten patients with primary pterygia. bservational Procedure: Subconjunctival ranibizumab (0.5 mg/0.05 mL) administered at the limbus, adjacent to pterygium either 3 days prior to surgery (Group 1, n = 5) or at the time of surgery (Group 2, n = 5). Patients prospectively followed for 6 months after injection. Main Outcome Measures: Safety and tolerability of subconjunctival ranibizumab as determined by patient reporting, clinical examination, and masked observer interpretation of slit-lamp photographs. Results: The median age at presentation was 59 years (range 33 to 71 years); 60% of patients were male. Five patients were randomly assigned to be injected with 0.05 mg ranibizumab via subconjunctival injection 3 days prior to surgery; an additional 5 patients were injected with ranibizumab at the time of surgery. All 10 patients tolerated the injection well. The conjunctival autograft remained intact in the 9 patients whose grafts were secured with sutures. There was dehiscence of the autograft in the 1 patient whose graft was secured with fibrin glue. No other safety concerns arose after 6 months of follow-up. Three pterygium recurrences were noted at 6 months (all patients in Group 1). All remaining patients had a normal surgical bed appearance. Conclusions: The data from this small pilot study suggest that 1 subconjunctival injection of ranibizumab in conjunction with pterygium surgery is well tolerated.

AB - Purpose: To evaluate the safety and tolerability of ranibizumab given via subconjunctival injection in patients with primary pterygium undergoing pterygium surgery with autograft placement. Design: Prospective, open-label pilot study. Methods: Setting: Single-center, academic practice. Study Population: Ten patients with primary pterygia. bservational Procedure: Subconjunctival ranibizumab (0.5 mg/0.05 mL) administered at the limbus, adjacent to pterygium either 3 days prior to surgery (Group 1, n = 5) or at the time of surgery (Group 2, n = 5). Patients prospectively followed for 6 months after injection. Main Outcome Measures: Safety and tolerability of subconjunctival ranibizumab as determined by patient reporting, clinical examination, and masked observer interpretation of slit-lamp photographs. Results: The median age at presentation was 59 years (range 33 to 71 years); 60% of patients were male. Five patients were randomly assigned to be injected with 0.05 mg ranibizumab via subconjunctival injection 3 days prior to surgery; an additional 5 patients were injected with ranibizumab at the time of surgery. All 10 patients tolerated the injection well. The conjunctival autograft remained intact in the 9 patients whose grafts were secured with sutures. There was dehiscence of the autograft in the 1 patient whose graft was secured with fibrin glue. No other safety concerns arose after 6 months of follow-up. Three pterygium recurrences were noted at 6 months (all patients in Group 1). All remaining patients had a normal surgical bed appearance. Conclusions: The data from this small pilot study suggest that 1 subconjunctival injection of ranibizumab in conjunction with pterygium surgery is well tolerated.

UR - http://www.scopus.com/inward/record.url?scp=77952543569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952543569&partnerID=8YFLogxK

U2 - 10.1016/j.ajo.2010.01.015

DO - 10.1016/j.ajo.2010.01.015

M3 - Article

C2 - 20417925

AN - SCOPUS:77952543569

VL - 149

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 6

ER -